Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar

Dr. Reddy's Lab launches Bupropion Hydrochloride Extended-Release Tablets

05 Sep 2019

Dr. Reddy's Laboratories has launched Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the US Food and Drug Administration (USFDA).

The Zyban brand and generic had US sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health. Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Related Dr. Reddy's Laboratories Ltd. Links:

Dr. Reddy's Lab Share Price

4889.15 -42.55 (-0.86%) Sep 17, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 770.25
Cipla 954.15
Dr. Reddy's Lab 4889.15
Aurobindo Pharma 745.80
Lupin 950.70
View more..
Sensex vs Dr. Reddy's Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback